TY - JOUR T1 - Current perspectives on the role of Interleukin-1 signaling in the pathogenesis of Asthma and COPD JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.00563-2019 SP - 1900563 AU - Emmanuel T. Osei AU - Corry-Anke Brandsma AU - Wim Timens AU - Irene H. Heijink AU - Tillie-Louise Hackett Y1 - 2019/01/01 UR - http://erj.ersjournals.com/content/early/2019/11/07/13993003.00563-2019.abstract N2 - Asthma and chronic obstructive pulmonary disease (COPD) cause significant morbidity and mortality worldwide. In the context of disease pathogenesis, both asthma and COPD involve chronic inflammation of the lung and are characterised by the abnormal release of inflammatory cytokines, dysregulated immune cell activity and remodeling of the airways. To date, current treatments still only manage symptoms and do not reverse the primary disease processes. In recent work, interleukin (IL)-1α and IL-1β have been suggested to play important roles in both asthma and COPD. In this review, we summarise overwhelming preclinical evidence for dysregulated signaling of IL-1α and IL-1β contributing to disease pathogenesis and discuss the paradox of IL-1therapeutic studies in asthma and COPD. This is particularly important given recent completed and ongoing clinical trials with IL-1 biologics that have had varying degrees of failure and success as therapeutics for disease modification in asthma and COPD.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Osei has nothing to discloseConflict of interest: Dr. Brandsma has nothing to disclose.Conflict of interest: Dr. Timens reports personal fees from Pfizer, personal fees from GSK, personal fees from Chiesi, from Roche Diagnostics / Ventana, grants from Dutch Asthma Fund, personal fees from Biotest, personal fees from Merck Sharp Dohme, personal fees from Novartis, personal fees from Lilly Oncology, personal fees from Boehringer Ingelheim, personal fees from Astra-Zeneca, personal fees from Bristol-Myers-Squibb, outside the submitted work.Conflict of interest: Dr. Heijink has nothing to disclose.Conflict of interest: Dr. Hackett has nothing to disclose. ER -